The feasibility and applications of non-invasive cardiac output monitoring, thromboelastography and transit-time flow measurement in living-related renal transplantation surgery: results of a prospective pilot observational study

Table 1 Demographic data for ten consecutive living-related donor renal transplant patients (P1 to P10) studied

Patient	Age (yrs)	Height (cm)	Weight (kg)	Body surface area (m²)	Body mass index (kg/m²)	Ethnicity	Dialysis status	Previous transplant	CMV (donor/recipient)	ESRF cause
P1	30	161	64	1.67	24.7	White European	HD^b (fistula)	N	-/+	Henoch-Schonlein Purpura
P2	45	177	101	2.18	32.2	White European	Pre-dialysis	N	-/-	?Hypertensive nephropathy
P3	41	179	77	1.96	24.0	White European	Pre-dialysis	N	-/-	FSGS^c
P4	24	157	50.4	1.49	20.4	White European	Pre-dialysis	N	+/+	?Hypertensive nephropathy
P5^a	41	157	66.4	1.67	26.9	South Asian	HD^b (vascath)	N	-/+	DM nephropathy
P6	44	185	83	2.07	24.3	White European	HD^b (fistula)	Y	-/-	Hypertensive (prev. traumatic nephrectomy)
								Cadaveric ×2 (1993/2010)
								^dAIT
P7	58	168	58.8	1.67	20.8	South Asian	HD^b (fistula)	N	+/+	Membranous nephropathy
P8	23	161	49.6	1.5	19.1	White European	CAPD	N	-/-	Chronic pyelonephritis
P9	48	169	77.4	1.88	27.1	White European	HD^b (fistula)	N	-/-	IgA nephropathy
P10	37	189	90.6	2.18	25.4	White European	Pre-dialysis	N	-/-	IgA nephropathy

^aP5 (highlighted) demonstrated DGF at 7-days post-operatively. ^bHD, haemodialysis; ^cFSGS, focal segmental glomerulosclerosis; ^dAIT, antibody incompatible transplantation.
Of the individuals studied, one incidence of DGF was noted (10%; P5). One intra-operative complication (10%; P3; thrombus at the arterial anastomosis, requiring thrombectomy and revision of the anastomosis) identified. One patient was postoperatively commenced on anti-rejection therapy (anti-thymoglobulin antibody) (10%; P7; within the period of follow-up, but did not demonstrate DGF).

ISSN: 2047-1440